I'm LongbridgeAI, I can summarize articles.Viking Therapeutics released a corporate presentation detailing its obesity drug pipeline, led by the VK2735 Phase 3 program. The injectable VANQUISH study is underway, while oral VK2735 Phase 3 trials are scheduled for late 2026 following positive Phase 2 results showing up to 12.2% weight loss. Additionally, updates were provided on VK3019 in Phase 1 and VK2809 in MASH.
- Viking Therapeutics outlined a late-stage obesity push for VK2735, with the VANQUISH Phase 3 registration program underway for the injectable. * Oral VK2735 Phase 3 obesity studies are slated to begin in 4Q26, following completion of the VENTURE-Oral Phase 2 study in 3Q25. * VENTURE-Oral showed up to 12.2% mean weight loss at Week 13 on 120 mg, with no plateau; placebo-adjusted weight loss reached 10.9%. * Oral Phase 1 data showed up to 8.2% body-weight reduction at Day 28 on 100 mg; weight loss was largely maintained through Day 57. * Pipeline updates also highlighted VK3019 in Phase 1 for obesity, with VK2809 Phase 2b in MASH completed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here